Julhash U. Kazi
- Hematology top 2%
- Acute Myeloid Leukemia Research 23
- Chronic Myeloid Leukemia Treatments 14
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 11
- Immunology top 5%
- Oncology top 5%
- Cancer-related Molecular Pathways 7
- Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer 14
- Protein Kinase Regulation and GTPase Signaling 12
- Protein Degradation and Inhibitors 10
-
- Acute Lymphoblastic Leukemia research 8
- Co-authors
- Lars RönnstrandKinjal ShahJianmin SunNuzhat N. KabirAmr Al‐HaidariJae‐Won SohAmilcar Flores‐MoralesS. M. Riazul Islam
- Cited by
- HematologyGeneticsImmunology
- Partner nations
- SwedenUnited StatesBangladesh
In The Last Decade
Julhash U. Kazi
81 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 540
- Genetics 295
- Immunology 443
- Oncology 514
- Molecular Biology 1.1k
Countries citing papers authored by Julhash U. Kazi
This map shows the geographic impact of Julhash U. Kazi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julhash U. Kazi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julhash U. Kazi more than expected).
Fields of papers citing papers by Julhash U. Kazi
This network shows the impact of papers produced by Julhash U. Kazi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julhash U. Kazi. The network helps show where Julhash U. Kazi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Julhash U. Kazi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 3 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 8 | |
| 9 | 2022 | 21 | |
| 10 | 2019 | 17 | |
| 11 | 2018 | 3 | |
| 12 | 2018 | 20 | |
| 13 | 2017 | 11 | |
| 14 | 2015 | 15 | |
| 15 | 2014 | 31 | |
| 16 | 2014 | 14 | |
| 17 | 2013 | 48 | |
| 18 | 2013 | 23 | |
| 19 | 2011 | 6 | |
| 20 | Celecoxib-induced growth inhibiton in SW480 colon cancer cells is associated with activation of protein kinase G | 2007 | 1 |
About Julhash U. Kazi
Julhash U. Kazi is a scholar working on Hematology, Genetics and Oncology, having authored 85 papers that have together received 2.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (23 papers), PI3K/AKT/mTOR signaling in cancer (14 papers), Chronic Myeloid Leukemia Treatments (14 papers), Protein Kinase Regulation and GTPase Signaling (12 papers), Chronic Lymphocytic Leukemia Research (11 papers), Protein Degradation and Inhibitors (10 papers), Acute Lymphoblastic Leukemia research (8 papers) and Cancer-related Molecular Pathways (7 papers). The work is most often cited by research in Hematology (540 citations), Genetics (295 citations) and Immunology (443 citations). Julhash U. Kazi has collaborated with scholars based in Sweden, United States and Bangladesh. Frequent co-authors include Lars Rönnstrand, Kinjal Shah, Jianmin Sun, Nuzhat N. Kabir, Amr Al‐Haidari, Jae‐Won Soh, Amilcar Flores‐Morales, S. M. Riazul Islam, Shruti Agarwal and Hui Zhao. Their work appears in journals such as Oncotarget, Blood, Cellular and Molecular Life Sciences, Oncogene and Molecular Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.